glp-1 receptor agonists and cardiovascular outcome trials an update Effects of on cardiometabolic outcomes in heart transplant recipients: A systematic review meta-analysis of observational studies Efficacy of GLP‐1 receptor agonists
Description
Yes, but do it tactfully
Heart Failure Benefits The most significant recent advancement has been the demonstration of profound benefits in heart failure with preserved ejection fraction (HFpEF) across multiple pivotal trials, establishing GLP-1 RAs as transformative therapy for obesity-related heart failure (Table 7)
The same manufacturer, Novo Nordisk, has another weight loss drug called Wegovy with the same active ingredient (semaglutide) that is FDA-approved for weight loss and some plans may only provide coverage for Wegovy if prescribed for weight loss and might only provide coverage for Ozempic if prescribed for diabetes
The Danish national prescription registry
Insulin is a relatively large peptide
